- Hypertrophic Cardiomyopathy (HCM)
- Vaccines: 2023 Year in Review
- Eyecare
- Urothelial Carcinoma
- Women's Health
- Hemophilia
- Heart Failure
- Vaccines
- Neonatal Care
- NSCLC
- Type II Inflammation
- Substance Use Disorder
- Gene Therapy
- Lung Cancer
- Spinal Muscular Atrophy
- HIV
- Post-Acute Care
- Liver Disease
- Pulmonary Arterial Hypertension
- Biologics
- Asthma
- Atrial Fibrillation
- Type I Diabetes
- RSV
- COVID-19
- Cardiovascular Diseases
- Breast Cancer
- Prescription Digital Therapeutics
- Reproductive Health
- The Improving Patient Access Podcast
- Blood Cancer
- Ulcerative Colitis
- Respiratory Conditions
- Multiple Sclerosis
- Digital Health
- Population Health
- Sleep Disorders
- Biosimilars
- Plaque Psoriasis
- Leukemia and Lymphoma
- Oncology
- Pediatrics
- Urology
- Obstetrics-Gynecology & Women's Health
- Opioids
- Solid Tumors
- Autoimmune Diseases
- Dermatology
- Diabetes
- Mental Health
Regional differences might exist in the cost of injectables
While the overall cost of injectables is relatively consistent from health plan to health plan, regional differences exist in the total cost of individual therapy classes as a result of PMPM utilization, necessitating payers to develop injectable management programs that are customized for their geographical service area. Examples of these regional differences include the higher incidence of multiple sclerosis in northern states, higher prevalence of older Americans in states such as Florida and Arizona (and the associated higher oncology costs), and infertility costs in states where coverage is state-mandated.
While the overall cost of injectables is relatively consistent from health plan to health plan, regional differences exist in the total cost of individual therapy classes as a result of PMPM utilization, necessitating payers to develop injectable management programs that are customized for their geographical service area. Examples of these regional differences include the higher incidence of multiple sclerosis in northern states, higher prevalence of older Americans in states such as Florida and Arizona (and the associated higher oncology costs), and infertility costs in states where coverage is state-mandated. Let's review the management of infertility drug costs, since it serves as an example of how therapy cost may vary from plan to plan.
TREATMENT STEPS Three basic steps exist in treating infertility: ovulation induction (OI), intrauterine insemination (IUI), and in-vitro fertilization (IVF). The table outlines the associated medications. OI should use generic oral medicines to stimulate ovulation, costing less than $50 per cycle. With approximately $1,000 in non-drug costs per cycle and three cycles total, costs average $3,500. IUI uses FSH and hCG together, which cost about $1,000 for the injectables and $1,000 in non-drug therapy per cycle. Average total treatment is approximately $6,000. IVF is the most costly of these treatments, and is performed after OI and IUI have failed. IVF uses a combination of FSH, hMG, hCG and GNRH or LHRH agonists. IVF costs about $4,500 in drug and $6,000 in non-drug treatment per cycle for one to six cycles, with a total treatment cost averaging about $36,000.
Kjel A. Johnson, PharmD, BCPS, FCCP, is vice president of strategic operations for ICORE Healthcare in Orlando.
A Conversation With Greg Baker, RPh, CEO of AffirmedRx
March 31st 2024Greg Baker, CEO of AffirmedRx, describes his early career, shares some of his critical opinions about the pharmacy benefit management (PBM) industry and how, in his view, his company is offering a better alternative.
Read More
David Calabrese of OptumRx Talks New Role, Market Insulin Prices and Other Topics 'On His Mind'
April 13th 2023In this month’s episode of the "What's On Your Mind podcast," Peter Wehrwein, managing editor of MHE connects with the now Chief Clinical Officer of OptumRx Integrated Pharmacies, David Calabrese. In this conversation, David touches on his transition in January as OptumRx’s former chief pharmacy officer and market president of health plans and PBMs to his new role as Chief Clinical Officer where he now focuses more on things such as specialty pharmacy to home delivery — with an overall goal of creating whole-patient care. Throughout the conversation, Calabrese also touched on the market’s hot topic of insulin prices and behavioral health services within the OptumRx community, among other topics.
Listen
Florida Gets the OK. But Will Drug Importation from Canada Actually Happen?
March 5th 2024Canadian health officials warn that maintaining a drug supply for Canadians is their priority. The staunch opposition of the U.S. pharmaceutical industry may also be an obstacle to imports from north of the border.
Read More
Briana Contreras, editor of Managed Healthcare Executive, spoke with Nancy Lurker, CEO and president of EyePoint Pharmaceuticals. Nancy shared a bit about EyePoint and how the organization’s innovative therapies are addressing patient needs through eye care, and most importantly, she addressed C-Suite positions like the CEO role. Nancy shared advice for those seeking to reach the CEO level, especially toward women in healthcare and other roles, and what it takes to run a biopharma company.
Listen
Lack of Diversity in Clinical Trials Hurts Research, and Costs Billions | AHA Scientific Sessions
November 12th 2023Healthcare researchers say it’s critical to get more women, Black and Latino participants in clinical trials. It can be done, but researchers and institutions must make the effort.
Read More
